Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Funck Robert E
2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2013
3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ABT]
(Last)
(First)
(Middle)
100 ABBOTT PARK ROAD
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Vice President, Controller
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

ABBOTT PARK, IL 60064
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common shares without par value 60,228
D
 
Common shares without par value 15,300 (1)
I
Profit Sharing Trust
Common shares without par value 500 (2)
I
By daughter
Common shares without par value 500 (2)
I
By daughter

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) (3) 02/18/2006 02/17/2015 Common shares 4,233 $ 22.267 D  
Option (right to buy) (3) 02/18/2007 02/17/2015 Common shares 4,233 $ 22.267 D  
Option (right to buy) (3) 02/18/2008 02/17/2015 Common shares 2,076 $ 22.267 D  
Option (right to buy) (3) 02/17/2007 02/16/2016 Common shares 8,667 $ 21.2194 D  
Option (right to buy) (3) 02/17/2008 02/16/2016 Common shares 8,666 $ 21.2194 D  
Option (right to buy) (3) 02/17/2009 02/16/2016 Common shares 8,667 $ 21.2194 D  
Option (right to buy) (3) 02/16/2008 02/15/2017 Common shares 8,934 $ 25.2461 D  
Option (right to buy) (3) 02/16/2009 02/15/2017 Common shares 8,933 $ 25.2461 D  
Option (right to buy) (3) 02/16/2010 02/15/2017 Common shares 8,933 $ 25.2461 D  
Option (right to buy) (3) 02/15/2009 02/14/2018 Common shares 8,500 $ 26.6973 D  
Option (right to buy) (3) 02/15/2010 02/14/2018 Common shares 8,500 $ 26.6973 D  
Option (right to buy) (3) 02/15/2011 02/14/2018 Common shares 8,500 $ 26.6973 D  
Option (right to buy) (3) 02/20/2010 02/19/2019 Common shares 4,267 $ 26.015 D  
Option (right to buy) (3) 02/20/2011 02/19/2019 Common shares 4,267 $ 26.015 D  
Option (right to buy) (3) 02/20/2012 02/19/2019 Common shares 4,266 $ 26.015 D  
Option (right to buy) (4) 02/19/2011 02/18/2020 Common shares 3,234 $ 26.1879 D  
Option (right to buy) (4) 02/19/2012 02/18/2020 Common shares 3,233 $ 26.1879 D  
Option (right to buy) (4) 02/19/2013 02/18/2020 Common shares 3,233 $ 26.1879 D  
Option (right to buy) (4) 02/18/2012 02/17/2021 Common shares 4,100 $ 22.3919 D  
Option (right to buy) (4) 02/18/2013 02/17/2021 Common shares 4,100 $ 22.3919 D  
Option (right to buy) (4) 02/18/2014 02/17/2021 Common shares 4,100 $ 22.3919 D  
Option (right to buy) (4) 02/17/2013 02/16/2022 Common shares 4,800 $ 27.0336 D  
Option (right to buy) (4) 02/17/2014 02/16/2022 Common shares 4,800 $ 27.0336 D  
Option (right to buy) (4) 02/17/2015 02/16/2022 Common shares 4,800 $ 27.0336 D  
Option (right to buy) (5) 08/02/2013 02/19/2014 Common shares 5,715 $ 33.88 D  
Option (right to buy) (5) 04/27/2013 02/19/2014 Common shares 2,137 $ 31.6081 D  
Option (right to buy) (4) 02/15/2014 02/14/2023 Common shares 21,234 $ 34.94 D  
Option (right to buy) (4) 02/15/2015 02/14/2023 Common shares 21,233 $ 34.94 D  
Option (right to buy) (4) 02/15/2016 02/14/2023 Common shares 21,233 $ 34.94 D  
Option (right to buy) (5) 08/20/2013 02/19/2014 Common shares 1,546 $ 35.08 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Funck Robert E
100 ABBOTT PARK ROAD
ABBOTT PARK, IL 60064
      Vice President, Controller  

Signatures

John A. Berry, Attorney-in-Fact for Robert E. Funck 03/08/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2013.
(2) The reporting person disclaims beneficial ownership of all securities held by his daughter.
(3) Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
(4) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
(5) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.